TDOC Stock Analysis Report for Bernini Capital
Introduction & Overview
We turn our attention to Teladoc Health, Inc. (TDOC), situated in the Health Information Services industry within the Healthcare sector. On 2025-05-15, TDOC’s shares were valued at $7.25, reflecting a bearish technical signal, trading beneath significant moving averages. Trading beneath these key SMAs usually points towards negative momentum in the near to medium term. With a market capitalization of approximately $1.32 B, TDOC represents a significant player in its field.
Our Bernini Capital review offers an in-depth look at Teladoc Health, Inc. (TDOC) with a focus on long-term value. We carefully assess its core financial stability, profit generation, cash flow (refer to Financial Health/Efficiency), and how its valuation stacks up against benchmarks. Dividend reliability (check Dividends section) is also examined.
Company Snapshot
Operationally, the company is engaged in: Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals …
Key Metrics Summary
Understanding TDOC’s valuation starts with these key data points. Comparing the current price ($7.25) to its 50-day ($7.27 – Below SMA 50) and 200-day ($9.41 – Below SMA 200) moving averages offers initial trend perspective. Volatility is 39.8%. Although the 1-year forecast targets $4.59, enduring investment choices depend more significantly on core fundamentals (like financial stability and earnings power) and if the price represents good value compared to its estimated worth.
Fundamental Business Profile
Fundamental Business Profile & Industry Standing
Assessing the company’s role within its industry, its operational scale, and its long-term strategy provides a foundation for fundamental valuation. Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counselling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.
Financial Health Assessment
For long-term investors, financial strength is key. We analyze profitability (ROE: -54.49%), leverage (111.19x), and liquidity (1.68x, 1.51x). Reliable positive cash flow from operations ($300.68 M) is essential for business health and shareholder returns. Benchmarking against peers 👥 is vital.
| Return on Equity (ROE TTM) | -54.49% |
| Return on Assets (ROA TTM) | -3.01% |
| Debt/Equity (MRQ) | 111.19x |
| Total Cash (MRQ) | $1.19 B |
| Total Debt (MRQ) | $1.59 B |
| Current Ratio (MRQ) | 1.68x |
| Quick Ratio (MRQ) | 1.51x |
| Operating Cash Flow (TTM) | $300.68 M |
| Levered Free Cash Flow (TTM) | $243.04 M |
Dividend & Shareholder Returns
For income-oriented value investors, analyzing shareholder returns is crucial. TDOC does not currently pay a significant regular dividend or data is unavailable. We assess the yield’s attractiveness relative to risk, the safety implied by the Payout Ratio (0.00%), and the history of dividend growth (data not shown here, requires further research 📜). Significant share repurchases are not indicated by available data. Total shareholder yield (Dividend Yield + Buyback Yield) provides a complete picture of capital return.
| Trailing Dividend Rate | $0.00 |
| Trailing Dividend Yield | 0.00x |
| Payout Ratio | 0.00x |
Value Investing Metrics
Fundamental valuation analysis is central to our process. We scrutinize P/E ratios (Trailing: N/A – is unavailable; Forward: -8.45x – below zero (suggesting no profit or data anomaly)), Price/Book (0.92x), and Price/Sales (0.52x). The Price/Free Cash Flow (P/FCF: 5.43x) 💵 is particularly vital, assessing value based on actual cash generation available to investors. Crucially, these ratios should be benchmarked against TDOC’s own historical averages 📜 and its industry peer group 👥 to determine relative attractiveness. A significant discount to historical/peer averages might indicate a value opportunity, provided fundamentals are sound (see Financial Health).
| Forward P/E | -8.45x |
| Price/Sales (TTM) | $0.52 |
| Price/Book (MRQ) | $0.92 |
| EV/Revenue (TTM) | 0.67x |
| EV/EBITDA (TTM) | 52.18x |
| Price/FCF (TTM) | $5.43 |
Profitability & Margin Stability
Consistent profitability and sustainable growth are cornerstones of long-term investment quality. We analyze Gross (70.48%), Operating (-8.73%), and Net Margins (-39.66%) for efficiency and competitive positioning. Recent expansion is reflected in Year-over-Year Revenue Growth (-2.60%) and Earnings Growth (N/A). Demonstrating resilient margins and the ability to grow earnings consistently, especially compared to peers 👥, strengthens the investment case.
| Profit Margin (TTM) | -39.66% |
| Operating Margin (TTM) | -8.73% |
| Gross Margin (TTM) | 70.48% |
| EBITDA Margin (TTM) | 1.29% |
| Revenue (TTM) | $2.55 B |
| Revenue Growth (YoY) | -2.60% |
| Gross Profit (TTM) | $1.80 B |
| EBITDA (TTM) | $32.82 M |
| Net Income (TTM) | $-1.01 B |
Market Perception Check
While analyst opinions are considered, they supplement rather than replace independent fundamental research. The current consensus is ‘Hold’ (19 analysts), with a mean target of $9.08 (Range: $7.00 – $12.00). Based on the mean target ($9.08), this implies a potential upside of ~25.2% from the current price ($7.25). Value investors should critically assess if the market price and analyst targets align with their own calculated intrinsic value and margin of safety requirements. Suggest reviewing analyst rationale if possible.
Conclusion & Outlook
Short-Term Technical Snapshot
- ▼Price Trend vs MAs: bearish (below SMA50/200)
- ▲Overall Technical Sentiment: Neutral-Bullish
- ●Momentum (RSI): Neutral (57.5)
- 📊Support / Resistance (30d): ~$6.35 / ~$7.72
Longer-Term Fundamental & Forecast Outlook
- ●Fundamental Health: Assessment Incomplete (ROE: -54.49%, D/E: 111.19x)
- ●Valuation Snapshot: Appears Moderate (Fwd P/E: -8.45x), P/FCF: 5.43x 💵
- ●Recent Growth (YoY): N/A (Rev: -2.60%, Earn: N/A)
- ▼1-Year Avg. Forecast: ~-36.7% avg. change to ≈$4.59
- ●Analyst Consensus: Hold (Target: $9.08)
Overall Assessment & Outlook
For long-term value investors, TDOC demonstrates a a moderate financial health profile (Assessment Incomplete (ROE: -54.49%, D/E: 111.19x)) and a valuation currently assessed as Appears Moderate (Fwd P/E: -8.45x), P/FCF: 5.43x 💵. The company does not offer a significant dividend. recent growth stands at N/A (Rev: -2.60%, Earn: N/A). Considering both technical momentum and fundamental drivers, the Neutral-Bullish technicals offer context on current market perception. Building a long-term position requires confidence in the company’s fundamentals, its market position, and buying at a price that provides sufficient margin for error. Investors should weigh these factors against identified risks and their individual investment horizon.
Note: This report combines model projections and public data for educational use. It is not investment advice. Market conditions change rapidly. Always conduct thorough independent research and consult a qualified financial advisor before making investment decisions.
Risk Factors
Understanding the risks associated with TDOC is crucial. Below are potential risks derived from analysis and market awareness; this overview is not fully comprehensive.
- ⚠️ General market downturns pose a risk to the share price.
- ⚠️ Headwinds within the Health Information Services/Healthcare space could negatively impact the company.
- ⚠️ Macroeconomic factors like inflation and interest rate changes present potential risks.
- ⚠️ Specific news or developments related to the company could affect its stock.
Frequently Asked Questions (FAQ)
What is the TDOC stock price prediction for the next year (2025-2026)?
The 1-year forecast average for TDOC stands at ≈$4.59, implying a -36.7% potential change relative to the current $7.25. This is an estimate; real-world factors will influence the actual price.
Will TDOC stock go up or down?
The 1-year forecast model suggests the price might trend sharply lower on average (-36.7% potential). However, short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently ‘Neutral-Bullish’), breaking news, and overall economic conditions. Technical indicators (see TA Summary) provide clues for near-term direction.
Is TDOC stock a good investment right now?
Value investors determine a ‘good buy’ by comparing price ($7.25) to intrinsic worth, seeking a safety margin. Examine fundamentals like debt (111.19x), earnings power, and valuation (e.g., -8.45x Fwd P/E). Is the potential reward worth the risk? Remember that general market risks are always present. Fundamentals, not just forecasts (-36.7% potential), drive long-term value. Remember, this analysis is for information only; seek professional advice before making investment decisions.
How volatile is TDOC stock?
Based on recent 30-day price action, TDOC’s annualized volatility is ≈39.8%. This level is currently considered typical, indicating the degree of recent price fluctuation. This is consistent with its market sensitivity (Beta: 1.83x). Higher volatility means larger potential price swings (both up and down).
What is TDOC’s P/E ratio and what does it mean?
Currently, TDOC’s Trailing P/E is N/A, assessed as unavailable. The Forward P/E multiple is -8.45x. This ratio shows the market price relative to earnings per share. Compare to industry peers and historical levels. A high P/E might be justified by rapid growth (refer to PEG).